Moffitt Cancer Center | Strategic Alliance Partners

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

Perry Kennedy, PhD, discusses the goals of the RAS Initiative.

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Treatment with CPX-351 led to a relative improvement in induction response of over 40% compared with conventional 7+3 cytarabine/daunorubicin in patients with secondary acute myeloid leukemia.

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses how personalized medicine may eventually help with preventing cancer.

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the significance of molecular testing for patients with melanoma and when testing should occur.

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.